Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction
CRISPR Therapeutics (NASDAQ:CRSP) said sales of Casgevy, the sickle cell and beta thalassemia therapy it shares with Vertex Pharmaceuticals (NASDAQ:VRTX) , reached $99 million in the third quarter. Shares fell about 2% in early after-hours trading. Casgevy is starting to pay CRISPR back, but the quarterly loss barely moved, so the pipeline still carries the stock. CRISPR doesn't book Casgevy sales itself. Vertex runs the launch, and the two split profits and costs 60/40. A year ago, CRISPR's share of costs far outran any income. Now sales are large enough to shrink that bill, and net collaboration expense fell about 28% from a year earlier. The loss still widened, but spending isn't the main reason. Operating loss narrowed slightly, even with a milestone payment to siRNA partner Sirius Therapeutics. The swing came from other income, which fell by about $7.5 million. The release doesn't say why. Continue reading